Reactive oxygen species responsive prodrug
A prodrug system targeting reactive oxygen species in the tumor microenvironment addresses the limitations of conventional anticancer drugs by selectively delivering and activating in cancer cells, enhancing treatment efficacy and safety.
Patent Information
- Application Number
- KR1020220190776
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-12-30
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2042-12-30
AI Technical Summary
Conventional anticancer drugs face challenges such as low bioavailability, low cancer cell specificity, toxicity to normal cells, difficulty penetrating the blood-brain barrier, and treatment resistance, particularly in glioblastoma, leading to poor prognosis and significant side effects.
A prodrug comprising a drug moiety, a reactive oxygen species reactive moiety, and an organ or cell targeting moiety, which transforms into an active metabolite specifically in the tumor microenvironment, allowing targeted delivery and activation in cancer cells.
The prodrug selectively kills cancer cells without harming normal cells, enables monitoring of drug targeting and therapeutic effects, and accumulates in cancer lesions through endocytosis, providing effective cancer diagnosis and treatment.
Smart Images

Figure 112022142473403-PAT00029_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a reactive oxygen species-reactive prodrug. Background Technology
[0002] Cancer is one of the leading causes of death worldwide, and the development of innovative cancer treatments can reduce medical costs while simultaneously generating high added value. Furthermore, according to 2008 statistics, molecular therapies capable of overcoming resistance to conventional anticancer drugs accounted for $17.5 billion in the seven major countries (US, Japan, France, Germany, Italy, Spain, and the UK). It is predicted that the market size will reach approximately $45 billion in 2018, showing a growth rate of 9.5% compared to 2008. Cancer treatment is classified into surgery, radiation therapy, chemotherapy, and biological therapy. Among these, chemotherapy is a treatment method that uses chemical substances to inhibit the proliferation or kill cancer cells. However, since the toxicity caused by anticancer drugs is largely manifested in normal cells as well, they exhibit a certain degree of toxicity. Additionally, because resistance develops and the effectiveness of anticancer drugs is lost after a certain period of use, there is an urgent need to develop anticancer drugs that act selectively on cancer cells and do not lead to resistance. Recently, the development of new anticancer drugs targeting the molecular characteristics of cancer is underway through the acquisition of molecular genetic information on cancer; however, there are reports that even anticancer drugs targeting characteristic molecular targets unique to cancer cells are developing drug resistance. Therefore, the development of anticancer drugs based on new concepts is necessary. Recently, there has been growing interest in strategies for cancer treatment that involve applying polypeptide-based prodrugs to specific cell receptors. However, there are problems associated with these prodrugs, such as their relatively complex manufacturing methods and relatively low targeting ability to specific sites, which can lead to them acting on normal tissues as well.
[0003] Glioblastoma multiforme (GBM) is the most malignant tumor among those originating from glial cells in the brain, characterized histologically by nuclear atypicality, mitotic patterns, vascular endothelial proliferation, and necrosis; it is the most common aggressive tumor in the brain. Malignant glioblastoma accounts for 12–15% of all brain tumors and 50–60% of gliomas, with an average 5-year survival rate of less than 7%. Glioblastoma is a very rapid-growing tumor, which causes a rapid increase in intracranial pressure, leading to headaches, nausea, and vomiting, while adults frequently experience seizures. Furthermore, the tumor itself or associated cerebral edema can impair the function of nearby nerves, resulting in various symptoms such as limb motor impairment, sensory loss, facial paralysis, speech disorders, cognitive decline, and left-right dysregulation. Since these neurological deficits in specific body parts vary significantly depending on the location of the tumor, a diagnosis cannot be made based on any single symptom alone. Various approaches have been proposed to treat glioblastoma, and existing treatments include chemotherapy using anticancer drugs following the surgical resection of cancer cells. When glioblastoma occurs, the tumor is generally removed as much as possible through surgery; however, since brain tissue can lead to serious complications if the tumor is removed indiscriminately simply because it is present, the extent of resection must be carefully determined. Once glioblastoma is histologically confirmed through the removed tissue, radiation therapy and chemotherapy are administered. However, conventional anticancer drugs used in chemotherapy have problems such as reduced therapeutic efficacy due to low bioavailability and low cancer cell specificity, which damage normal cells as well as cancer cells and lead to various side effects; furthermore, they have difficulty penetrating the blood-brain barrier (A. Peixoto, M. Relvas-Santos, R. Azevedo, LL Santos and JA Ferreira, Frontiers in Oncology, 2019, 9.). In addition, despite treatments including surgery, radiation therapy, and chemotherapy, treatment resistance is very high, and the prognosis after treatment is poor. The problem to be solved
[0004] The objective of the present invention is to provide a prodrug.
[0005] In addition, the objective of the present invention is to provide a pharmaceutical composition for the diagnosis and treatment of cancer. means of solving the problem
[0006] To achieve the above objective, the present invention provides a prodrug comprising a drug moiety; a reactive oxygen species reactive moiety; a linker; and an organ or cell targeting moiety.
[0007] A pharmaceutical composition for the diagnosis and treatment of cancer comprising a prodrug is provided. Effects of the invention
[0008] Since the prodrug of the present invention is administered in an inactive form and specifically reacts only with reactive oxygen species in the tumor microenvironment to transform into an active metabolite, it does not cause side effects to normal cells other than cancer cells. Because it can deliver the drug specifically to the organ where cancer has occurred or to cancer cells, it has the effect of selectively killing only the targeted cancer, and thus can be utilized for the diagnosis and treatment of cancer. Furthermore, since it accumulates in cancer lesions through endocytosis of targeted cells, it has the effect of allowing monitoring of the drug's targeting and therapeutic effects. Brief explanation of the drawing
[0009] Figure 1 is a diagram showing the process of synthesizing the reactive oxygen species reactive moiety Y of Chemical Formula 7. Figure 2 is a diagram showing the process of synthesizing a cancer-targeting prodrug of Chemical Formula 1. Figure 3 shows the results of the absorption spectrum analysis of GBM prodrugs, Free X, and Y-linker-Z. Figure 4 shows the results of the fluorescence spectrum analysis of the GBM prodrug, Free X, and Y-linker-Z. Figure 5 is a figure showing the extent of Free X release due to the degradation of GBM prodrugs over time under hydrogen peroxide conditions, confirmed by fluorescence spectrum analysis. Figure 6 is a figure showing the extent of Free X release due to the decomposition of GBM prodrugs according to hydrogen peroxide concentration, confirmed by fluorescence spectrum analysis. Figure 7 shows the results of confirming the selective activation ability of the GBM prodrug for hydrogen peroxide through changes in fluorescence intensity. Figure 8 shows the results of fluorescent imaging of the activation of the GBM prodrug by intracellularly induced reactive oxygen species after treating glioblastoma cells (U87MG) with the GBM prodrug. Figure 9 shows the results of evaluating the cytotoxicity of the GBM prodrug U87MG and whether there was an increase in cytotoxicity caused by induced reactive oxygen species. Figure 10 shows the results of fluorescent imaging of the glioblastoma-specific targeting effect and drug activation effect according to the expression of glioblastoma-specific receptors of GBM prodrugs. Figure 11 is a figure confirming the glioblastoma-specific killing effect of a GBM prodrug. Figure 12 is a schematic diagram showing the mechanism of action of a GBM prodrug. Specific details for implementing the invention
[0010] Hereinafter, the present invention will be described in detail with reference to the attached drawings and embodiments thereof. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom.
[0011] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.
[0012] All technical terms used in this invention, unless otherwise defined, are used in the sense generally understood by those skilled in the art in the relevant field of this invention. Additionally, while preferred methods or samples are described herein, similar or equivalents are also included within the scope of this invention. The contents of all publications cited as references in this specification are incorporated into this invention.
[0014] In one aspect, the present invention relates to a drug delivery system comprising an active oxygen species reactive moiety; a linker; and an organ or cell targeting moiety.
[0015] In one embodiment, the reactive oxygen species reactive moiety may be arylboronic acids; prochelators; organochalcogen including selenides (selenols and hydrogen selenide), sulfides, disulfides and thioethers; sulfonate esters; thiazolidinones (TZ) or quinones.
[0016] In one embodiment, the reactive oxygen species reactive moiety may include a compound of the following chemical formula 7:
[0017] [ Chemical formula 7 ]
[0018] .
[0019] In one embodiment, the linker may be a peptide linker, a non-peptide linker, or a linker in which the peptide linker and the non-peptide linker are mixed; the peptide linker may be an in vivo cleavage type peptide linker or an in vivo non-cleavage type linker; and the non-peptide linker may be polyethylene glycol (PEG), maleimide, 5-aminovaleric acid (5AVA), or trioxatridecan-succinamic acid (Ttds).
[0020] In one embodiment, the drug delivery vehicle may include a compound of the following formula 2 that exhibits blue fluorescence:
[0021] [ Chemical formula 2 ]
[0022] .
[0023] In one embodiment, the compound of Formula 2 can exhibit a maximum fluorescence wavelength at 430 nm.
[0024] In one aspect, the present invention relates to a prodrug comprising a drug moiety; a reactive oxygen species reactive moiety; a linker; and an organ or cell targeting moiety.
[0025] In one embodiment, the drug moiety may be an anticancer agent, and the anticancer agent is SN-38 (7-ethyl-10-hydroxy-camptothecin), daunorubicin, doxorubicin, epirubicin, idarubicin, pixantrone, sabarubicin, valrubicin, paclitaxel, docetaxel, mechloethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine: CCNU), streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, dactinomycin (actinomycin D), plicamycin, mitomycin C, vincristine, vinblastine, teniposide, topotecan, iridotecan, uramustine, melphalan, bendamustine, dacarbazine, temozolomide, altretamine, duocarmycin, nedaplatin, oxaliplatin, Satraplatin, triplatin tetranitrate, 5-fluorouracil,6-mercaptopurine, capecitabine, cladribine, clofarabine, cystarbine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, thioguanine, etoposide, mitoxantrone, izabepilone, vindesine, vinorelbine, estramustine, maytansine, DM1 (mertansine), DM4, It may be selected from the group consisting of dolastatin, auristatin E, auristatin F, monomethyl auristatin E, monomethyl auristatin F, and derivatives thereof.
[0026] In one embodiment, the prodrug of the present invention may release a drug moiety in response to reactive oxygen species (ROS), and the reactive oxygen species are superoxide anions (O₂). 2- ), hydroxyl radical (HO˙), hydrogen peroxide (H2O2), hypochlorous acid (HOCl), or singlet oxygen (singlet oxygen, 1 It could be O2.
[0027] In one embodiment, the reactive oxygen species reactive moiety may be arylboronic acids; prochelators; organochalcogen including selenides (selenols and hydrogen selenide), sulfides, disulfides and thioethers; sulfonate esters; thiazolidinones (TZ) or quinones.
[0028] In one embodiment, the reactive oxygen species reactive moiety may include a compound of the following chemical formula 7:
[0029] [ Chemical formula 7 ]
[0030] .
[0031] In one embodiment, the linker may be a peptide linker, a non-peptide linker, or a linker in which the peptide linker and the non-peptide linker are mixed; the peptide linker may be an in vivo cleavage type peptide linker or an in vivo non-cleavage type linker; and the non-peptide linker may be polyethylene glycol (PEG), maleimide, 5-aminovaleric acid (5AVA), or trioxatridecan-succinamic acid (Ttds).
[0032] In one embodiment, the prodrug of the present invention may comprise a compound of the following formula 9, wherein X is a drug moiety:
[0033] [ Chemical formula 9 ]
[0034] .
[0035] In one embodiment, the organ or cell targeting moiety may be a conjugate of a peptide or peptidomimetic comprising or composed of an organ or cell targeting sequence, and may be a conjugate of SIWV, iRGD, Cilengitide, SFITGv6, CNGRC, RGDechi, DAG, ZD2, CSG, BT1718, Dox-TAT, RGD-SSL-Dox, LPD-PEG-NGR, VWCS, FWCS, TAT-Bim, Poropeptide-Bax, R8-Bax, CT20p-NP, RRM-MV, RRM-IL12, PNC-27, PNC-21, or PNC-28, or a mime thereof.
[0036] In one embodiment, the organ or cell targeting moiety may target a cell surface antigen or an autoantigen, and the cell surface antigen may be one or more selected from the group consisting of CEA, ED-B fibronectin, CD20, CD22, CD19, EGFR, IGF1R, VEFGR1 / Flt-1, VEGFR2 / KDR, VEGRF3 / Flt-4, HER2 / neu, CD30, CD33, CD3, CD16, CD64, CD89, CD2, adenovirus fibrous nop, PfMSP-1, HN / NDV, EpCAM / 17-1A, hTR, IL-2R / Tac, CAl9-9, MUCl, HLA class II, GD2, G250, TAG-72, PSMA, CEACAM6, HMWMAA, CD40, M13 envelope protein, and GPIIb / IIIa.
[0037] In one embodiment, the organ or cell targeting moiety may comprise an antibody or a fragment having immunological activity thereof, and the fragment having immunological activity may be any one selected from the group consisting of Fab, Fd, Fab', dAb, F(ab'), F(ab')2, scFv, Fv, single-strand antibody, Fv dimer, complementarity determining region fragment, humanized antibody, chimeric antibody, and diabody.
[0038] In one embodiment, the organ or cell targeting moiety may be a caveolin receptor targeting peptide.
[0039] In one embodiment, the organ or cell targeting moiety may be a cell-penetrating peptide (CPP), a caveolin receptor-specific cell-penetrating peptide that penetrates / is taken up into the cell through the caveolin receptor, and a peptide comprising the amino acid sequence of SEQ ID NO. 1.
[0040] The term "cell-permeable peptide" as used in the present invention is a peptide that enters a cell through a permeation pathway using specific molecules such as heparan sulfate, clathrin, caveolin, and phospholipid expressed on the cell membrane.
[0041] In one embodiment, the organ or cell targeting moiety may target a cancer cell-specific biomarker, and the cancer cell-specific biomarker is 17-1A antigen, GD3 ganglioside R24, EGFRvⅢ, PSMA, PSCA, HLA-DR, EpCAM, MUC1 core protein, atypically glycosylated MUC1, fibronectin isoform containing an ED-B domain, HER2 / neu, carcinoma-embryonic antigen (CEA), gastrin-releasing peptide (GRP) receptor antigen, mucin antigen, epidermal growth factor receptor (EGF-R), HER3, HER4, MAGE antigen, SART antigen, MUC1 antigen, c-erb-2 antigen, TAG 72, carbonic anhydrase IX, alpha-fetoprotein, antigen specific to A3 and A33 antibodies, Ba 733, BrE3-antigen, CA125, CDl, CD1a, CD3, CD5, CDl5, CD16, CD19, CD20, CD21, CD22, CD23, CD25, CD30, CD33, CD38, CD40, CD45, CD52, CD74, CD79a, CD80, CD138, Colon-specific antigen-p (CSAp), CSAp, EGP-1, EGP-2, Ep-CAM, FIt-1, Flt-3, Folate receptor, HLA-DR, Human chorionic gonadotropin (HCG) and its subunits, Hypoxia-inducible factor (HIF-I), Ia, IL-2, IL-6, IL-8, Insulin-growth factor-1 (IGF-1), KC4-antigen, KS-1-antigen, KSl-4, Le-Y, Macrophage inhibition Factor (MIF), MAGE, MUCl, MUC2, MUC3, MUC4, NCA66, NCA95, NCA90, antigen specific to PAM-4 antibody, placental growth factor, p53, prostatic acid phosphatase, PSA, RS5, SLOO, TAC, tenascin, TRAIL receptors, Tn antigen,It may be one or more selected from the group consisting of Thomson-Friedenreich antigens, tumor necrosis antigens, VEGF, ED-B fibronectin, angiogenesis markers, oncogene markers, or oncogene products, and the oncogene may be an apoptosis-related gene, a transcription factor gene, a metastasis-related gene, angiogenesis-related gene, or a tyrosine-kinase gene.
[0042] In one embodiment, the apoptosis-related gene is ABL1, AKT1, AKT2, BARD1, BAX, BCL11B, BCL2, BCL2A1, BCL2L1, BCL2L12, BCL3, BCL6, BIRC2, BIRC3, BIRC5, BRAF, CARD11, CAV1, CBL, CDC25A, CDKN1A, CFLAR, CNR2, CTNNB1, CUL4A, DAXX, DDIT3, E2F1, E2F3, E2F5, ESPL1, FOXO1, HDAC1, HSPA5, IGF1R, IGF2, JUN, JUNB, JUND, MALT1, MAP3K7, MCL1, MDM2, MDM4, MYB, MYC, NFKB2, NPM1, NTRK1, PAK1, It may be PAX3, PML, PRKCA, PRKCE, PTK2B, RAF1, RHOA, TGFB1, TNFRSF1B, TP73, TRAF6, YWHAG, YWHAQ, or YWHAZ;상기 전사인자 유전자는 AR, ARID3A, ASCL1, ATF1, ATF3, BCL11A, BCL11B, BCL3, BCL6, CDC5L, CDX2, CREB1, CUX1, DDIT3, DLX5, E2F1, E2F3, E2F5, ELF4, ELK1, ELK3, EN2, ERG, ETS1, ETS2, ETV1, ETV3, ETV4, ETV6, FEV, FEZF1, FLI1, FOS, FOSL1, FOXA1, FOXG1, FOXM1, FOXO1, FOXP1, FOXQ1, GATA1, GATA6, GFI1, GFI1B, GLI1, GLI2, GLI3, HES6, HHEX, HLF, HMGA1, HMGA2, HOXA1, HOXA9, HOXD13, HOXD9, ID1, ID2, IKZF1, IRF2, IRF4, JUN, JUNB, JUND, KAT6A, KDM2A, KDM5B, KLF2, KLF4, KLF5, KLF6, KLF8, KMT2A, LEF1, LHX1, LMX1B, MAF, MAFA, MAFB, MBD1, MECOM, MEF2C, MEIS1, MITF, MYB, MYC, MYCL, MYCN, NANOG, NCOA3, NFIB, NFKB2, NKX2-1, OTX2, PATZ1, PAX2, PAX3, PAX4, PAX8, PBX1, PBX2, PITX2, PLAG1,PLAGL2, PPARG, PPP1R13L, PRDM10, PRDM13, PRDM14, PRDM15, PRDM16, PRDM6, PRDM8, PRDM9, RARA, REL, RERE, RUNX1, RUNX3, SALL4, SATB1, SFPQ, SIX1, SNAI1, SOX2, SOX4, SPI1, SREBF1, STAT3, TAF1, TAL1, TAL2, TBX2, TBX3, TCF3, TFCP2, TFE3, THRA, TLX1, TP63, TP73, TWIST1, WT1, YBX1, YY1, ZBTB16, ZBTB7A, ZIC2, ZNF217 또는 ZNF268일 수 있고;The above metastasis-related gene may be AKT1, AKT2, AR, CBL, CDH1, CRK, CSF1, CTNNB1, CTTN, CXCR4, EGFR, FGFR1, FLT3, FYN, GLI1, ILK, ITGA3, JAK2, MET, PDGFRB, PLXNB1, PRKCI, PTCH1, PTPN11, RAC1, RHOA, RHOC, ROCK1, SMO, SNAI1, SRC, TCF3, or WT1; and the above angiogenesis-related gene may be BRAF, CAV1, CTGF, EGFR, ERBB2, ETS1, FGF4, FGF6, FGFR1, FGFR3, FGFR4, ID1, NRAS, PDGFB, PDGFRA, PDGFRB, or SPARC; The above tyrosine-kinase gene may be ABL1, ABL2, ALK, AXL, BLK, EGFR, EPHA2, ERBB2, ERBB3, ERBB4, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT3, FYN, ITK, JAK1, JAK2, KIT, LCK, MERTK, MET, MST1R, NTRK1, NTRK3, PDGFRA, PDGFRB, PTK2B, PTK7, RET, ROS1, SRC, SYK, TEC, or YES1.
[0043] 일 구현예에서, 종양유전자는 SEPTIN9, ACOD1, ACTN4, ADAM28, ADAM9, ADGRF1, ADRBK2, AFF1, AFF3, AGAP2, AGFG1, AGRN, AHCYL1, AHI1, AIMP2, AKAP13, AKAP9, AKIRIN2, AKTIP, ALDH1A1, ALL1, ANIB1, ANP32C, ANP32D, AQP1, ARAF, ARHGEF1, ARHGEF2, ARHGEF5, ASPSCR1, AURKA, BAALC, BAIAP2L1, BANP, BCAR4, BCKDHB, BCL9, BCL9L, BCR, BMI1, BMP7, BOC, BRD4, BRF2, CABIN1, CAMK1D, CAPG, CBFB, CBLB, CBLL1, CBX7, CBX8, CCDC28A, CCDC6, CCNB1, CCNB2, CCND1, CCNE1, CCNL1, CD24, CDC25C, CDC6, CDH17, CDK1, CDK14, CDK4, CDK5R2, CDK6, CDK8, CDKN1B, CDKN3, CDON, CEACAM6, CENPW, CHD1L, CHIC1, CHL1, CKS1B, CMC4, CNTN2, COPS3, COPS5, CRKL, CRLF2, CROT, CRTC1, CRYAB, CSF1R, CSF3, CSF3R, CSNK2A1, CSNK2A2, CT45A1, CTBP2, CTNND2, CTSZ, CUL7, CXCL1, CXCL2, CXCL3, CYGB, CYP24A1, DCD, DCUN1D1DDB2, DDHD2, DDX6, DEK, DIS3, DNPH1, DPPA2, DPPA4, DSG3, DUSP12, DUSP26, ECHS1, ECT2, EEF1A1, EEF1A2, EEF1D, EIF3E, EIF3I, EIF4E, EIF5A2, ELAVL1, ELL, EML4, EMSY, ENTPD5, EPCAM, EPS8, ERAS, ERGIC1, ERVW-1, EVI2A, EVI5, EWSR1, EZH2, FAM189B, FAM72A,FAM83D, FASN, FDPS, FGF10, FGF3, FGF5, FGF8, FR1OP, FHL2, FIP1L1, FNDC3B, FRAT1, FUBP1, FUS, FZD2, GAB2, GAEC1, GALNT10, GALR2, GLO1, GMNN, GNA12, GNA13, GNAI2, GNAQ, GNAS, GOLPH3, GOPC, GPAT4, GPM6A, GPM6B, GPR132, GREM1, GRM1, GSK3A, GSM1, H19, HAS1, HAX1, HDGFRP2, HMGN5, HNRNPA1, HOTAIR, HOTTIP, HOXA-AS2, HRAS, HSPA1A, HSPA4, HSPB1, HULC, IDH1, IFNG, IGF2BP1, IKBKE, IL7R, INPPL1, INTS1, INTS2, INTS3, INTS4, INTS5, INTS7, INTS8, IRS2, IST1, JUP, KDM4C, KIAA0101, KIAA1524, KIF14, KRAS, KSR2, LAMTOR5, LAPTM4B, LCN2, LDHB, LETMD1, LIN28A, LIN28B, LMO1, LMO2, LMO3, LMO4, LSM1, LUADT1, MACC1, MACROD1, MAGEA11, MALAT1, MAML2, MAP3K8, MAPRE1, MAS1, MCC, MCF2, MCF2L, MCTS1, MEFV, MFHAS1, MFNG, MIEN1, MINA, MKL2, MLANA, MLLT1, MLLT11, MLLT3, MLLT4, MMP12, MMS22L, MN1, MNAT1, MOS, MPL, MPST, MRAS, MRE11A, MSI1, MTCP1, MTDH, MTOR, MUC1, MUC4, MUM1, MYD88, NAAA, NANOGP8, NBPF12, NCOA4, NEAT1, NECTIN4, NEDD4, NEDD9, NET1, NINL, NME1, NOTCH1, NOTCH4, NOV, NSD1, NUAK2, NUP214, NUP98, NUTM1, OLR1,PA2G4, PADI2, PAK7, PARK7, PARM1, PBK, PCAT1, PCAT5, PDGFA, PDZK1IP1, PELP1, PFN1P3, PIGU, PIK3CA, PIK3R1, PIM1, PIM2, PIM3, PIRD, PLK18PM1,1, PPP1R10, PPP1R14A, PPP2R1A, PRAME, PRDM12, PRMT5, PSIP1, PSMD10, PTCH2, PTMA, PTP4A1, PTP4A2, PTP4A3, PTTG1, PTTG1IP, PTTG2, R21, RAB1, PVTAB, RAB8A, RALGDS, RAP1A, RASSF1, RBM14, RBM15, RBM3, RBMY1A1, RFC3, RGL4, RGR, RHO, RING1, RINT1, RIT1, RNF43, RPL23, RRAS, RRAS2, RSF14, S100T, S1X1T S100A8, SAG, SART3, SBSN, SEA, SEC62, SERTAD1, SERTAD2, SERTAD3, SET, SETBP1, SETDB1, SGK1, SIRT1, SIRT6, SKI, SKIL, SKP2, SLC12A5, SLCNO3A2, SCG9, SMR1,B, SNORA80E, SPAG9, SPATA4, SPRY2, SQSTM1, SRSF1, SRSF2, SRSF3, SRSF6, SS18, SSX1, SSX2, SSX2B, STIL, STMN1, STRA6, STYK1, SUZTA101CSTD, SSW TAF15, TALDO1, TAZ, TBC1D1, TBC1D15, TBC1D3, TBC1D3C, TBC1D7, TCL1A, TCL1B, TCL6, TCP1, TFG, TGM3, TINCR, TKTL1, TLE1, TMEMPR140,2, TMPRSSPD2, TMPOP2 TRE17, TREH, TRIB1, TRIB2,TRIM28, TRIM32, TRIM8, TRIO, TRIP6, TSPAN1, TSPY1, TXN, TYMS, TYRP1, UBE2C, UBE3C, UCA1, UCHL1, UHRF1, URI1, USP22, USP4, USP6, VAV1, VAV2, VAV3, VIM, WAPL, WHSC1, WHSC1L1, WISP1, It may be WNT1, WNT10A, WNT10B, WNT2, WNT3, WNT5A, WWTR1, XCL1,
[0044] In one embodiment, the cell targeting moiety may be a cancer cell targeting moiety, and the cancer cell targeting moiety may be a peptide, a small molecule compound, or a protein that binds to the cancer cell-specific biomarker.
[0045] In one embodiment, the prodrug of the present invention may comprise a compound of the following formula 1, wherein X is a drug moiety; Y is a reactive oxygen species reactive moiety; and Z is an organ or cell targeting moiety:
[0046]
[0047] In one embodiment, the compound of Formula 1 can exhibit a maximum absorption wavelength at 370 nm and a maximum fluorescence wavelength at 430 nm under conditions of an aqueous solution (pH 7.4).
[0048] In one embodiment, the compound of Formula 1 may react with intracellular reactive oxygen species to break the quenching effect caused by photoinduced electron transfer and increase fluorescence, and may decompose into the following Y-linker-Z (Formula 2) and free X, which exhibit blue fluorescence upon reaction with reactive oxygen species, thereby releasing a drug moiety in the form of free X:
[0049]
[0050] In one embodiment, the compound of Formula 2 can exhibit a maximum fluorescence wavelength at 430 nm.
[0051] In one embodiment, the drug moiety released by decomposition from the prodrug of the present invention in reaction with reactive oxygen species may be a compound of Formula 3 exhibiting strong yellow fluorescence, and the compound of Formula 3 may exhibit a maximum fluorescence wavelength at 560 nm:
[0052]
[0053] In one embodiment, the organ or cell targeting moiety Z may be a caveolin receptor-specific cell-permeating peptide that permeates into / is taken up by a caveolin receptor, and may be a peptide containing the amino acid sequence of SEQ ID NO. 1, and a prodrug containing this as the organ or cell targeting moiety Z may target brain cancer cells, and it is more preferable to target glioblastoma.
[0054] In one embodiment, the prodrug can improve the tumor targeting rate of the prodrug through endocytosis mediated by a glioblastoma-specific receptor (e.g., caveolin receptor, which is a glioblastoma overexpressed receptor).
[0055] In one embodiment, the prodrug of the present invention may be transformed into an active metabolite in response to hypoxic conditions, overexpressed reactive oxygen species, and acidic conditions collectively referred to as the tumor microenvironment in an inactive state.
[0056] In one embodiment, the prodrug of the present invention can be used as a drug delivery system.
[0057] In one embodiment, the prodrug of the present invention may further comprise a labeling moiety, and the labeling moiety may comprise one or more selected from the group consisting of a chromogenic enzyme, a radioisotope, a chromopore, a luminescent substance, and a fluorescent substance, and the fluorescent substance may be a fluorescent substance of the Cy (cyanine) series, Rhodamine series, Alexa series, BODIPY series, or ROX series, and may be Nile Red, BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene), cyanine, fluorescein, Rhodamine, coumarine, or Alexa.
[0058] In one aspect, the present invention relates to a pharmaceutical composition for the diagnosis and treatment of cancer, comprising the prodrug of the present invention as an active ingredient.
[0059] In one embodiment, the composition may enable simultaneous diagnosis and treatment of cancer.
[0060] In one embodiment, the cancer may be a solid tumor and may be a glioblastoma, brain tumor, melanoma, multiple myeloma, non-small cell lung cancer, oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cervical cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, fallopian tube carcinoma, proanal cancer, endometrial carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, lymphoma, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, kidney or ureteral cancer, renal cell carcinoma, renopelvic carcinoma, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brainstem glioma or pituitary adenoma. It is more desirable that it be a glioblastoma.
[0061] As used in this invention, the term "treatment" refers to any act of improving or beneficially altering the symptoms of a disease or condition and its resulting complications through the administration of a composition according to this invention. A person skilled in the art to which this invention pertains would be able to determine the precise criteria for diseases to which the composition of this invention is effective, and to assess the degree of improvement, enhancement, and treatment, by referring to materials provided by organizations such as the Korean Medical Association.
[0062] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used in the present invention, the term "pharmaceuticalally effective amount" refers to an amount sufficient to treat or diagnose a disease with a reasonable benefit / risk ratio applicable to medical treatment or diagnosis. The effective dose level may be determined based on factors including the patient's disease type and severity, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. Other pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all the above-mentioned factors, and this can be easily determined by a person skilled in the art. Therefore, when used in humans, the dosage should be determined as an appropriate amount by considering both safety and efficiency. It is also possible to estimate the amount used in humans from the effective amount determined through animal experiments. These factors to consider when determining an effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and EW Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.
[0063] The pharmaceutical composition of the present invention may include a carrier, a diluent, an excipient, or a combination of two or more of these commonly used in biological preparations. As used in the present invention, the term "pharmaceutical acceptable" means exhibiting properties that are not toxic to cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, and may be used, for example, compounds listed in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed. Additionally, diluents, dispersants, surfactants, binders, and lubricants may be added to formulate the composition into primary formulations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or component using appropriate methods in the field or methods disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0064] In one embodiment, the pharmaceutical composition may be one or more formulations selected from the group comprising oral formulations, topical preparations, suppositories, sterile injectable solutions, and sprays, and an oral or injectable formulation is more preferred.
[0065] As used in the present invention, the term "administration" means providing a specific substance to an individual or patient by any appropriate method. Depending on the intended method, it may be administered parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or locally as an injectable formulation) or orally. The dosage varies depending on the patient's body weight, age, gender, health status, diet, time of administration, method of administration, excretion rate, and severity of the disease. Liquid formulations for oral administration of the composition of the present invention include suspensions, liquid formulations, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories, etc. The pharmaceutical composition of the present invention may also be administered by any device capable of delivering the active substance to target cells. Preferred modes of administration and formulations include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, drip infusions, etc. Injectables can be prepared using aqueous solvents such as physiological saline solution and Ringer's solution, vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), non-aqueous solvents, and may include pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
[0066] The term "individual" as used in the present invention refers to all animals, including monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, bats, camels, rats, rabbits, or guinea pigs, including humans, that have developed or may develop the said disease or disorder.
[0067] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight with respect to the composition, but is not limited thereto.
[0068] In one aspect, the present invention relates to a kit for simultaneously diagnosing and treating cancer, comprising a pharmaceutical composition for the diagnosis and treatment of cancer according to the present invention.
[0070] The present invention will be explained in more detail through the following examples. However, the following examples are intended only to illustrate the content of the present invention and do not limit the present invention.
[0072] Example 1. Preparation of reactive oxygen species reactive moiety Y (Chemical Formula 7)
[0073] 1-1. Preparation of the compound of Chemical Formula 4
[0074]
[0075] Sodium hydride (NaH, 4.8 g, 200 mmol) was dissolved in anhydrous dimethyl sulfoxide (50 mL). The mixture was stirred and cooled to 0 °C. Subsequently, anhydrous dimethyl sulfoxide (60 mL) containing 3,4-dihydroxybenzaldehyde (13.8 g, 100 mmol) was added dropwise to the mixture. The mixture was stirred at room temperature (25 °C) for 30 minutes, after which propargyl bromide (11.1 mL, 100 mmol) was added and stirred overnight at room temperature. After the reaction was complete, the results were analyzed by thin layer chromatography (TLC, silica gel 60F-254 glass plate, Merck). The product was neutralized with a hydrochloric acid solution (HCl, 1 M) and extracted with ethyl acetate (3 × 250 mL), and the organic layer was dried with anhydrous sodium sulfate (Na2SO4, 5 g). The resulting compound was purified using silica gel column chromatography (developing solvent: ethyl acetate / n-hexane / acetic acid = 20:80:1) to prepare the compound of Chemical Formula 4. Compounds from each synthesis step were dissolved in a CDCl3 (δ, 7.26 ppm) solution to prepare samples for analysis, and a Bruker DRX-500 NMR Spectrometer (manufactured by Bruker) was used 1 H NMR, 13 Structural analysis was performed by measuring C NMR.
[0077] 1-2. Preparation of the compound of Chemical Formula 5
[0078]
[0079] The compound of Formula 4 (1.0 g, 5.68 mmol) prepared in Example 1-1 above and 4-bromomethyl phenylboronic acid pinacol ester (1.68 g, 5.68 mmol) were dissolved in acetonitrile (20 mL), and the mixture was stirred overnight at 80 °C. After the reaction was complete, it was analyzed by thin-film chromatography (developing agent: 1:4 ( v / v ) ethyl acetate:n-hexane) was used, and after filtering, the solvent was evaporated to prepare the compound of Chemical Formula 5 above in a bright yellow, viscous liquid state. 1 H NMR (500 MHz, CDCl3): δ9.81 (s, 1H), 7.82 (d, J = 7.54 Hz, 2H), 7.55 (t, J = 1.74 Hz, 1H), 7.44-7.40 (m, 3H), 6.96 (dd, J = 8.28, 1.62 Hz, 1H), 5.24 (s, 2H), 4.81 (d, J = 2.4 Hz, 2H), 2.55 (t, J = 2.4 Hz, 1H), 1.33 (s, 12H). 13 C NMR (125 MHz, CDCl3): 190.63, 154.00, 147.62, 138.93, 135.05, 130.01, 127.00, 126.18, 112.95, 83.78, 77.85, 76.35, 70.67, 56.75, 24.76 ppm.
[0081] 1-3. Preparation of the compound of chemical formula 6
[0082]
[0083] The compound of Formula 5 (1.60 g, 4.08 mmol) prepared in Examples 1-2 above and sodium borohydride (NaBH 4,0.31 g (8.16 mmol) was dissolved in methanol (methanol, 10 mL), and the mixture was stirred at room temperature for 2 hours. After the reaction was finished, it was analyzed by thin-film chromatography. Subsequently, the mixture was purified using column chromatography with silica gel (developing agent: ethyl acetate / n-hexane = 1:4 to 1:2) to prepare the compound of Chemical Formula 6, which has a bright yellow solid form. 1 H NMR (500 MHz, CDCl3): δ7.82-7.79 (m, 2H), 7.44-7.41 (m, 2H), 7.08 (d, J = 1.85 Hz, 1H), 6.87 (dd, J = 8.25, 1.90 Hz, 1H), 6.83 (d, J = 8.25 Hz, 1H), 5.16 (s, 2H), 4.77 (d, J = 2.40 Hz, 2H), 4.58 (d, J = 4.60 Hz, 2H), 2.51 (t, J = 2.40 Hz, 1H), 1.86 (br s, 1H), 1.34 (s, 12H). 13 C NMR (125 MHz, CDCl3): 148.33, 147.45, 140.14, 134.95, 134.13, 126.28, 120.91, 114.55, 114.49, 83.78, 78.70, 75.73, 70.99, 64.97, 57.04, 24.80 ppm.
[0085] 1-4. Preparation of the compound of Chemical Formula 7
[0086]
[0087] The compound of Formula 6 (1.20 g, 3.04 mmol) prepared in Examples 1-3 above and phosphorus tribromide (PBr 3,0.41 g (1.52 mmol) was dissolved in dichloromethane (30 mL) at 0 °C. The mixture was stirred overnight at room temperature, and after the reaction was complete, it was analyzed by thin-film chromatography. Subsequently, the mixture was cooled to 0 °C and neutralized using sodium hydrogen sulfate (NaHSO4). Then, it was extracted with dichloromethane (3 x 30 mL) and the organic layer was dried with anhydrous sodium sulfate (5 g). Afterward, the mixture was purified using column chromatography with silica gel (developing medium: ethyl acetate / n-hexane = 1:4 to 1:2) to prepare a pale yellow solid compound of Chemical Formula 7 (Fig. 1), which was named the reactive oxygen species reactive moiety Y. 1 H NMR (500 MHz, CDCl3): δ7.82-7.79 (m, 2H), 7.44-7.41 (m, 2H), 7.10 (d, J = 2.10 Hz, 1H), 6.93 (dd, J = 8.30, 2.10 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 5.17 (s, 2H), 4.79 (d, J = 2.35 Hz, 2H), 4.47 (s, 2H), 2.53 (t, J = 2.35 Hz, 1H), 1.34 (s, 12H). 13 C NMR (125 MHz, CDCl3): 149.00, 147.22, 139.80, 134.93, 130.56, 126.20, 122.99, 116.24, 114.11, 83.72, 78.38, 75.95, 70.79, 57.04, 33.88, 24.76 ppm.
[0089] Example 2. Synthesis of cancer-targeting prodrugs
[0090] 2-1. Binding of anticancer drug X to reactive oxygen species reactive moiety Y
[0091]
[0092] Drug X (0.10 g, 0.25 mmol) and cesium carbonate (Cs2CO 3, 0.10 g (0.30 mmol) was dissolved in dry dimethylformamide (10 mL), and the compound of Formula 7 (active oxygen species reactive moiety Y) prepared in Examples 1-4 (0.34 g, 0.75 mmol) was added to the mixture and stirred overnight at room temperature. After the reaction, the organic layer was extracted with ethyl acetate and dried with anhydrous sodium sulfate (5 g). The mixture was then purified using column chromatography with silica gel (developing medium: methanol / dichloromethane = 1:99 to 2:99) to prepare a pale yellow solid compound (Formula 8) in which an anticancer agent X is bound to the active oxygen species reactive moiety Y. 1 H NMR (500 MHz, CDCl3): δ8.13 (d, J = 9.25 Hz, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.60 (s, 1H), 7.52 (dd, J = 9.25, 2.65 Hz, 1H), 7.43 (d, J = 7.9 Hz, 2H), 7.21 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 2.65 Hz, 1H), 7.03 (dd, J = 8.30, 1.80 Hz, 1H), 6.91 (d, J = 8.30 Hz, 1H), 5.75 (d, J = 16.15 Hz, 1H), 5.30 (d, J = 16.20 Hz, 1H), 5.23 (s, 2H), 5.19 (s, 2H), 5.17 (s, 2H), 4.80 (d, J = 2.40 Hz, 2H), 3.74 (br s, 1H), 3.10 (q, J= 7.65 Hz, 2H), 2.45 (t, J = 2.35 Hz, 1H), 1.95-1.82 (m, 2H), 1.34 (s, 12H), 1.33 (t, J = 7.70 Hz, 3H), 1.03 (t, J = 7.38 Hz, 3H). 13 C NMR (125 MHz, CDCl3): 173.80, 157.70, 157.57, 150.22, 149.47, 148.95, 147.56, 147.00, 145.13, 143.73, 140.01, 135.10, 135.04, 132.01, 132.00, 129.09, 127.99, 127.25, 126.31, 122.67, 121.77, 118.00, 115.07, 114.47, 103.15, 97.63, 83.86, 78.63, 75.99, 72.96, 70.94, 70.20, 66.20, 57.16, 49.40, 31.61, 24.90, 23.14, 13.55, 7.91 ppm.
[0094] 2-2. Linker Connection
[0095]
[0096] The compound of Formula 8 (XY) (15 mg, 0.02 mmol) and the linker (MW = 2,000 g / mol, 39 mg, 1 equiv.) prepared in Example 2-1 above were dissolved in a dichloromethane / methanol (2:1, total = 10 mL) solution, and then sodium ascorbate (10 mol%) was added to the mixture and stirred for 30 minutes while degassing with argon gas. During this time, copper sulfate pentahydrate (CuSO4·5H2O) dissolved in methanol (0.5 mL) was degassing with argon gas. After 30 minutes, the degassing copper sulfate pentahydrate solution was added to the mixture and stirred for 8 hours. After the reaction was completed, the results were analyzed by thin-film chromatography. Afterwards, the mixture was purified using column chromatography with silica gel (developing agent: methanol / dichloromethane = 1:19 to 2:8) to prepare the compound of Chemical Formula 9 with a linker attached to XY.
[0098] 2-3. Synthesis of Cancer-Targeting Prodrugs
[0099] [ Chemical formula 1 ]
[0100]
[0101] In order to produce a prodrug capable of selectively treating only cancer cells by changing into an active metabolite in response to overexpressed reactive oxygen species (especially hydrogen peroxide), which is one of the specific tumor microenvironment conditions of the cell, a cancer-targeting prodrug was synthesized by conjugating a targeting peptide Z to a compound (Chemical Formula 9) in which reactive oxygen species reactive moiety Y, anticancer agent X, and a linker are combined to change into an active metabolite under the tumor microenvironment conditions prepared in the above example. Specifically, the compound of Formula 9 (2 mg, 1 equiv.) and peptide Z (0.51 mg, 1 equiv.) prepared in Example 2-2 above were dissolved in distilled water (DI H2O, 0.5 mL), and the mixture was stirred at 4 ℃ for 4 hours to obtain the prodrug of Formula 1 (XY-linker-Z) without further purification (Fig. 2).
[0103] Example 3. Preparation of a glioblastoma-targeted prodrug
[0104] As an example of a cancer-targeting prodrug, a glioblastoma-targeting prodrug (GBM prodrug) was synthesized by applying the X moiety to the anticancer agent SN-38 (7-ethyl-10-hydroxy-camptothecin), the linker to PEG, and the Z moiety to the peptide SIWV (SEQ No. 1) that targets glioblastoma multiforme (GBM), in the cancer-targeting prodrug of Example 2, which consists of an active oxygen species-reactive moiety Y, an anticancer agent X, a linker to GBM.
[0106] Example 4. Characterization of GBM prodrugs
[0107] 4-1. Analysis of Absorption and Fluorescence Characteristics in Aqueous Solution
[0108] Under conditions where the solvent was an aqueous solution (pH 7.4), the absorbance and fluorescence intensity of the GBM prodrug prepared in Example 3, and Free X (SN38, Formula 3) and Y-linker-Z (Formula 2) (10 μM each) degraded by activation upon exposure of the GBM prodrug to reactive oxygen species were measured. An absorption spectrophotometer (UV / Vis spectrophotometer; Agilent, California, USA) was used to analyze the absorption spectra, and a fluorescence spectrophotometer (SHIMADZU CORP. RF-6000, Japan) was used to analyze the fluorescence spectra. For each spectrum measurement, a standard quartz cell (internal volume = 0.1 cm, Hellma Analytics, Jena, Germany) with sides 1 cm thick was used.
[0109] Absorption spectrum analysis of the GBM prodrug, Free X, and Y-linker-Z showed a peak absorption value at 370 nm (Fig. 3). In addition, fluorescence spectrum analysis showed that Y-linker-Z exhibited fluorescence at 430 nm and Free X at 560 nm, whereas the GBM prodrug exhibited lower fluorescence compared to Y-linker-Z and Free X due to the quenching effect caused by photoinduced electron transfer (Fig. 4).
[0111] 4-2. Analysis of Fluorescence Change Over Time Under Hydrogen Peroxide Conditions
[0112] Fluorescence spectrum analysis was performed to determine the extent of Free X release due to the degradation of GBM prodrugs over time (0–12 hours) in a 37°C aqueous solution (pH 7.4) containing hydrogen peroxide (1 mM). At this time, the release of Free X due to the degradation of GBM prodrugs was confirmed by yellow emission at 560 nm, and the byproduct Y-linker-Z (byproduct) was confirmed by blue emission at 430 nm.
[0113] As a result, the degradation of GBM prodrugs by hydrogen peroxide was found to increase over time and become more active under the same concentration of hydrogen peroxide (Fig. 5).
[0115] 4-3. Analysis of Fluorescence Changes According to Hydrogen Peroxide Concentration
[0116] After reacting for 12 hours in an aqueous solution (pH 7.4) at 37 ℃ under conditions of hydrogen peroxide concentration of 0 to 1 mM, fluorescence spectrum analysis was performed to confirm the release of Free X from the GBM prodrug.
[0117] As a result, it was found that the emission of Free X at 560 nm increased as the hydrogen peroxide concentration increased (Fig. 6).
[0119] 4-4. Selective Reactivity Analysis of Hydrogen Peroxide
[0120] To confirm the selectivity of the GBM prodrug for hydrogen peroxide, the GBM prodrug (10 μM) was added to an aqueous solution (pH 7.4 PBS buffer) containing various metal ions or biomolecules (Sigma Aldrich, TCI, Alfa) at a concentration of 100 μM, stirred at 37 °C for 1 hour, and then the fluorescence intensity was measured using a spectrofluorophotometer.
[0121] As a result, it was found that the GBM prodrug did not react when exposed to each metal ion and biomolecule, so the fluorescence intensity did not increase, whereas it showed selectivity by reacting only when exposed to hydrogen peroxide, resulting in an increase in fluorescence intensity (Fig. 7).
[0123] 4-5. Analysis of Intracellular Absorption and Activation Efficiency
[0124] The intracellular uptake efficiency and activation efficiency of GBM prodrugs were confirmed by treating U87MG (human primary glioblastoma cell line) with GBM prodrugs. Specifically, U87MG cells (Korea Cell Line Bank) were cultured in DMEM (Dulbecco's modified eagle's medium, Hyclone, US) supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin streptomycin (Gibco), and then approximately 2 × 10⁶ U87MG cells were placed on the bottom of a confocal glass dish (SPL). 5 After dispensing in the specified number, the cells were cultured in a 37°C, 5% CO2 incubator for approximately 24 hours. Subsequently, to induce intracellular reactive oxygen species, TBHP ( tertThe cells were pretreated with TBHP (150 μM) for 3 hours and treated with GBM prodrug (10 μM) for 6 hours at 37 °C. After 6 hours of incubation, the cells were washed three times with DPBS (Dulbecco's phosphate buffered saline, Hyclone) and fixed with 4% paraformaldehyde (10 min). Subsequently, the activation of the GBM prodrug by intracellularly induced reactive oxygen species by TBHP was visualized using a confocal laser scanning microscope (CLSM). The GBM prodrug was observed at excitation wavelengths and emission channels of 405 / 422 nm and 400–500 nm, while Free X was observed at excitation wavelengths and emission channels of 405 / 553 nm and 500–700 nm.
[0125] As a result, U87MG cells treated with the GBM prodrug showed significant changes in fluorescence in both the blue and yellow channels, and when the GBM prodrug was applied after pretreatment with TBHP, which induces intracellular reactive oxygen species, the change in fluorescence intensity in the yellow channel of U87MG cells was found to increase (Fig. 8).
[0127] Through this, it was confirmed that the release of Free X increased as GBM prodrugs were activated and degraded by intracellularly induced reactive oxygen species.
[0129] Example 5. Confirmation of the glioblastoma-killing effect of a GBM prodrug
[0130] To confirm the anticancer effect of GBM prodrugs against glioblastoma, cytotoxicity experiments were performed using U87MG cells with a cytotoxicity kit (Cell Counting Kit-8; CCK-8, Product No. CK04-13, Dojindo Molecular Tech. Inc, Tokyo, Japan). Specifically, approximately 5 x 10⁶ cells were placed in a 96-well plate (SPL, 30096). 3 After aliquoting 10 U87MG cells, at 37°C, 5% CO2 The samples were cultured for 24 hours. Subsequently, to observe changes depending on the induction of reactive oxygen species, the experiment was divided into two groups: one treated with TBHP (150 μM) for 3 hours followed by GBM prodrug treatment, and the other treated with GBM prodrug alone. In this experiment, the GBM prodrug was diluted in the culture medium and administered at various concentrations (0–10 μM). After culturing each group for 48 hours, they were washed three times with DPBS, and then 10 μL of CCK-8 solution, diluted in the culture medium, was added to each well. After culturing for 2 hours, the absorbance was measured at 450 nm, and the percentage of cytotoxicity was calculated as (sample absorbance * 100) / (control absorbance). Absorbance was measured using a microplate reader (Multichan FC, Thermo Fisher).
[0131] As a result, it was found that the GBM prodrug killed glioblastoma in a concentration-dependent manner. At high concentrations of 1 μM or higher, there was no significant difference between the group treated only with the GBM prodrug and the group activated; however, at low concentrations, the killing effect on glioblastoma was significantly increased when the GBM prodrug was activated with reactive oxygen species (Fig. 9).
[0133] Example 6. Confirmation of GBM prodrug targeting glioblastoma
[0134] To confirm the glioblastoma-specific targeting effect of GBM prodrugs mediated by the Z moiety, the intracellular uptake efficiency and activation efficiency of GBM prodrugs were evaluated according to the expression of glioblastoma-specific receptors. Specifically, U87MG and Huh7 (human hepatocellular carcinoma cell lines) (Korean Cell Line Bank) were cultured in DMEM medium supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin streptomycin (Gibco), and then placed on the bottom of a confocal glass dish at a volume of approximately 2 × 10⁶ 5After dispensing each sample in equal numbers, they were incubated in a 37°C, 5% CO2 incubator for approximately 24 hours. Subsequently, GBM prodrug (10 μM) was added and incubated at 37°C for 12 hours, followed by washing three times with DPBS and fixation with 4% paraformaldehyde for 10 minutes. Afterward, using a confocal laser scanning microscope, the GBM prodrug was observed at excitation wavelengths and emission channels of 405 / 422 nm and 400–500 nm, and Free X was observed at excitation wavelengths and emission channels of 405 / 553 nm and 500–700 nm.
[0135] As a result, U87MG cells treated with the GBM prodrug showed changes in fluorescence intensity in both blue and yellow channels compared to U87MG cells not treated with the GBM prodrug (Fig. 10), confirming that the endocellularly introduced GBM prodrug was activated by intracellular reactive oxygen species. On the other hand, Huh7 cells treated with the GBM prodrug showed lower changes in fluorescence intensity in both blue and yellow channels compared to U87MG cells treated with the GBM prodrug (Fig. 10).
[0137] Through this, it was confirmed that the GBM prodrug has an excellent targeting effect on U87MG cells expressing glioblastoma-specific receptors and exhibits efficient drug activation.
[0139] Example 7. Confirmation of the selective apoptotic effect of a GBM prodrug on glioblastoma
[0140] To confirm the selective killing effect of the GBM prodrug on glioblastoma, U87MG cells and Huh7 cells were treated with the GBM prodrug (0–10 μM) and cultured for 48 hours, and then cytotoxicity tests were performed using the CCK-8 assay to confirm the glioblastoma cell-specific anticancer effect.
[0141] As a result, the GBM prodrug selectively exhibited cytotoxicity in glioblastoma (U87MG cell line) compared to hepatocellular carcinoma (Huh7 cell line) (Fig. 11), confirming that the GBM prodrug can specifically treat glioblastoma without toxic side effects on other cells.
Claims
Claim 1 Prodrug comprising the compound of the following chemical formula 9: [Chemical Formula 9] In the above chemical formula 9, X is a drug moiety, the drug moiety is an anticancer agent, and the anticancer agent is SN-38 (7-ethyl-10-hydroxy-camptothecin). Claim 2 delete Claim 3 delete Claim 4 In claim 1, the compound is a prodrug that improves the cancer cell targeting rate. Claim 5 In claim 4, the cancer cells are a prodrug, which is a glioblastoma. Claim 6 In claim 1, the compound is a prodrug that specifically kills cancer cells. Claim 7 In claim 6, the above cancer cells are a prodrug, which is a glioblastoma. Claim 8 In claim 1, the above compound is a prodrug that reacts with the amino acid of SEQ ID NO.
1. Claim 9 delete Claim 10 delete Claim 11 delete Claim 12 delete Claim 13 delete Claim 14 delete Claim 15 delete Claim 16 In claim 1, the prodrug is a prodrug that releases a drug moiety in the form of Free X in response to reactive oxygen species. Claim 17 A pharmaceutical composition for the diagnosis and treatment of cancer comprising the prodrug of claim 1 as an active ingredient. Claim 18 A pharmaceutical composition for the diagnosis and treatment of cancer, capable of simultaneous diagnosis and treatment, according to claim 17. Claim 19 In paragraph 17, for the diagnosis and treatment of cancer, which is glioblastoma, brain tumor, melanoma, multiple myeloma, non-small cell lung cancer, oral cancer, liver cancer, gastric cancer, colon cancer, breast cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cervical cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, fallopian tube carcinoma, proanal cancer, endometrial carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, lymphoma, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, renal or ureteral cancer, renal cell carcinoma, renopelvic carcinoma, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brainstem glioma or pituitary adenoma Pharmaceutical composition.
